A study to assess and compare safety and efficacy of acarbose, vildagliptin and saxagliptin in the treatment of T2DM patients and gut microbiota
Latest Information Update: 29 Apr 2021
At a glance
- Drugs Acarbose (Primary) ; Saxagliptin (Primary) ; Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 01 Jun 2021 Results published in the Life Sciences
- 29 Apr 2021 New trial record